1-benzyl-N-[4-[[[7-methyl-2-[(3S)-3-methylpiperazin-1-yl]quinazolin-4-yl]amino]methyl]phenyl]piperidine-4-carboxamide | 1190746-98-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-benzyl-N-[4-[[[7-methyl-2-[(3S)-3-methylpiperazin-1-yl]quinazolin-4-yl]amino]methyl]phenyl]piperidine-4-carboxamide
• CAS: 1190746-98-5
• 化学式: C₃₄H₄₁N₇O
• 分子量: 563.746
• InChiKey: LOKRMKSVZVZJDI-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  85.4
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-benzyl-N-(4-{[(2-chloro-7-methylquinazolin-4-yl)amino]methyl}phenyl)piperidine-4-carboxamide 、 (S)-(+)-2-甲基哌嗪 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 1-benzyl-N-[4-[[[7-methyl-2-[(3S)-3-methylpiperazin-1-yl]quinazolin-4-yl]amino]methyl]phenyl]piperidine-4-carboxamide
  参考文献：
  名称：

  2,4-Diamino-quinazolines as inhibitors of β-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer

  摘要：

  The synthesis and SAR of a series of 2,4-diamino-quinazoline derivatives as beta-catenin/Tcf-4 inhibitors are described. This series was developed by modifying the initial lead 1, which was identified by screening of our compound library and found to inhibit the beta-catenin/Tcf-4 pathway. Replacement of the biphenyl moiety in compound 1 with the N-phenylpiperidine-4-carboxamide chain as in 2, resulted in a number of new analogues, which are potent inhibitors of the beta-catenin/Tcf-4 pathway. Compound such as 16k exhibited good cellular potency, solubility, metabolic stability and oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.070

文献信息

• 2,4-Diamino-quinazolines as inhibitors of β-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer
  作者：Zecheng Chen、Aranapakam M. Venkatesan、Christoph M. Dehnhardt、Osvaldo Dos Santos、Efren Delos Santos、Semiramis Ayral-Kaloustian、Lei Chen、Yi Geng、Kim T. Arndt、Judy Lucas、Inder Chaudhary、Tarek S. Mansour

  DOI：10.1016/j.bmcl.2009.07.070

  日期：2009.9

  The synthesis and SAR of a series of 2,4-diamino-quinazoline derivatives as beta-catenin/Tcf-4 inhibitors are described. This series was developed by modifying the initial lead 1, which was identified by screening of our compound library and found to inhibit the beta-catenin/Tcf-4 pathway. Replacement of the biphenyl moiety in compound 1 with the N-phenylpiperidine-4-carboxamide chain as in 2, resulted in a number of new analogues, which are potent inhibitors of the beta-catenin/Tcf-4 pathway. Compound such as 16k exhibited good cellular potency, solubility, metabolic stability and oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.